Equities Analysts Offer Predictions for BCYC FY2025 Earnings

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) – Equities researchers at Cantor Fitzgerald raised their FY2025 earnings estimates for shares of Bicycle Therapeutics in a research report issued to clients and investors on Monday, August 11th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($3.73) per share for the year, up from their previous forecast of ($3.87). The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. Cantor Fitzgerald also issued estimates for Bicycle Therapeutics’ FY2026 earnings at ($3.59) EPS.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.19). The company had revenue of $2.90 million for the quarter, compared to analyst estimates of $9.43 million. Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative return on equity of 32.43%.

A number of other equities analysts have also recently issued reports on the stock. Royal Bank Of Canada set a $27.00 price objective on shares of Bicycle Therapeutics and gave the company an “outperform” rating in a research note on Monday. Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. B. Riley dropped their price objective on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a “neutral” rating for the company in a research note on Friday, May 2nd. Oppenheimer restated an “outperform” rating and issued a $44.00 price objective (down previously from $48.00) on shares of Bicycle Therapeutics in a research note on Monday. Finally, Morgan Stanley dropped their price objective on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating for the company in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $22.22.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $7.35 on Wednesday. Bicycle Therapeutics has a 52-week low of $6.10 and a 52-week high of $28.67. The stock has a market cap of $508.99 million, a price-to-earnings ratio of -2.09 and a beta of 1.44. The firm has a fifty day moving average of $7.90 and a 200-day moving average of $8.91.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds have recently made changes to their positions in BCYC. Barclays PLC increased its position in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock worth $37,000 after purchasing an additional 2,345 shares in the last quarter. Nan Fung Group Holdings Ltd increased its position in shares of Bicycle Therapeutics by 118.3% during the 4th quarter. Nan Fung Group Holdings Ltd now owns 68,943 shares of the company’s stock worth $965,000 after purchasing an additional 37,358 shares in the last quarter. Long Focus Capital Management LLC bought a new stake in Bicycle Therapeutics during the 4th quarter worth about $7,603,000. Jane Street Group LLC grew its holdings in Bicycle Therapeutics by 18.9% during the 4th quarter. Jane Street Group LLC now owns 23,991 shares of the company’s stock worth $336,000 after acquiring an additional 3,811 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in Bicycle Therapeutics by 2.1% during the 4th quarter. Bank of America Corp DE now owns 392,859 shares of the company’s stock worth $5,500,000 after acquiring an additional 7,994 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.